A Multicentre, Randomised, Open-labelled, Parallel-group, Activecontrolled Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 52 Weeks in Previously Human Growth Hormone Treated Japanese Adults With Growth Hormone Deficiency
收藏DataCite Commons2025-12-05 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012052/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This trial is conducted in Asia. The aim of this trial is to evaluate the safety of once weekly dosing of somapacitan (NNC0195-0092) and daily Norditropin® FlexPro® for 52 weeks in previously human growth hormone treated Japanese adults with growth hormone deficiency.
提供机构：
Vivli
创建时间：
2025-12-05
